Form 4: Karen Smith Acquires Skye Bioscience Stock Options

Director Karen L. Smith acquired 75,000 stock options in Skye Bioscience, Inc. on March 31, 2026.

Summary

• Karen L. Smith, a Director at Skye Bioscience, Inc., acquired 75,000 stock options on March 31, 2026.
• These options have an exercise price of $0.615 and are exercisable starting March 31, 2026, with an expiration date of March 31, 2036.
• The stock options vest in equal monthly installments over a one-year period beginning March 31, 2026.
• Following this transaction, Karen L. Smith beneficially owns 75,000 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it represents standard executive compensation and potential long-term alignment, but does not indicate immediate financial performance changes.

Positives

• Director Karen L. Smith has acquired a significant number of stock options, indicating potential confidence in the company's future performance.
• The acquisition of options with a long-term expiration date (10 years) suggests a long-term growth perspective.

Future Outlook

The stock options vest over one year starting March 31, 2026, and expire in 2036, suggesting a long-term outlook for the company's stock value.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common form of executive compensation and can signal management's belief in the company's future prospects within the biotechnology sector.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment and long-term confidence in the company.

Next Steps

• The stock options will vest in equal monthly installments over the one-year period beginning March 31, 2026.

Key Dates

Keywords

stock options, Skye Bioscience, insider trading, director acquisition, equity compensation, Form 4, SEC filing